New JAK2 inhibitors for myeloproliferative neoplasms

Bibliography

• Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;20:1-5
   Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22
   PubMed Web of Science ®Google Scholar
• Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-90
   PubMed Web of Science ®Google Scholar
• Beer PA, Green AR. Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2009:621-8
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007;109:5104-11
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Barbui T, Di Gennaro L, The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007;136:249-59
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997;89:2319-27
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Grossi A, Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Soraru M, Dominietto A, Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010;45:458-63
   PubMed Web of Science ®Google Scholar
• Stewart WA, Pearce R, Kirkland KE, The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010;45:1587-93
   PubMed Web of Science ®Google Scholar
• Kroger N, Holler E, Kobbe G, Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264-70
   PubMed Web of Science ®Google Scholar
• Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008;22:474-86
   PubMed Web of Science ®Google Scholar
• Arana-Yi C, Quintas-Cardama A, Giles F, Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006;11:929-43
   PubMed Web of Science ®Google Scholar
• Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009;113:5394-400
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Manshouri T, Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27:4760-6
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yao X, Cripe LD, Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. Blood 2010;116:4436-8
   PubMed Web of Science ®Google Scholar
• Prchal JF, Axelrad AA. Letter: bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382
   PubMed Web of Science ®Google Scholar
• Lutton JD, Levere RD. Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera. Acta Haematol 1979;62:94-9
   PubMed Web of Science ®Google Scholar
• Adamson JW, Fialkow PJ, Murphy S, Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-16
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Blanchard KL, Levy J, Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 1991;88:6848-52
   PubMed Web of Science ®Google Scholar
• el Kassar N, Hetet G, Li Y, Clonal analysis of haemopoietic cells in essential thrombocythaemia. Br J Haematol 1995;90:131-7
   PubMed Web of Science ®Google Scholar
• Tsukamoto N, Morita K, Maehara T, Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 1994;86:253-8
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97
   PubMed Web of Science ®Google Scholar
• Zhao R, Xing S, Li Z, Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine RL, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68
   PubMed Web of Science ®Google Scholar
• Pietra D, Li S, Brisci A, Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-9
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke C, Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3
   PubMed Web of Science ®Google Scholar
• Wang YL, Vandris K, Jones A, JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2008;22:1289
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A, Lim KH, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-11
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T, MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844-7
   PubMed Web of Science ®Google Scholar
• Beer PA, Campbell PJ, Scott LM, MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141-9
   PubMed Web of Science ®Google Scholar
• Tahiliani M, Koh KP, Shen Y, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930-5
   PubMed Web of Science ®Google Scholar
• Ito S, D'Alessio AC, Taranova OV, Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010;466:1129-33
   PubMed Web of Science ®Google Scholar
• Oh ST, Simonds EF, Jones C, Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:988-92
   PubMed Web of Science ®Google Scholar
• Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010;363:1189-90
   PubMed Web of Science ®Google Scholar
• Jager R, Gisslinger H, Passamonti F, Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010;24:1290-8
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-6
   PubMed Web of Science ®Google Scholar
• Carbuccia N, Murati A, Trouplin V, Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-6
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Manshouri T, Patel J, Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-52
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-70
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM, IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 2010;24:1146-51
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Abdel-Wahab O, IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010;24:1302-9
   PubMed Web of Science ®Google Scholar
• Grand FH, Hidalgo-Curtis CE, Ernst T, Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92
   PubMed Web of Science ®Google Scholar
• Jones AV, Chase A, Silver RT, JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009;41:446-9
   PubMed Web of Science ®Google Scholar
• Kilpivaara O, Mukherjee S, Schram AM, A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009;41:455-9
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Harutyunyan A, Jager R, A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009;41:450-4
   PubMed Web of Science ®Google Scholar
• Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20:3387-95
   PubMed Web of Science ®Google Scholar
• Lucet IS, Fantino E, Styles M, The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107:176-83
   PubMed Web of Science ®Google Scholar
• Lu X, Levine R, Tong W, Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005;102:18962-7
   PubMed Web of Science ®Google Scholar
• Silva M, Richard C, Benito A, Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564-71
   PubMed Web of Science ®Google Scholar
• Wernig G, Mercher T, Okabe R, Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-81
   PubMed Web of Science ®Google Scholar
• Lacout C, Pisani DF, Tulliez M, JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652-60
   PubMed Web of Science ®Google Scholar
• Zaleskas VM, Krause DS, Lazarides K, Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006;1:e18
   PubMed Web of Science ®Google Scholar
• Bumm TG, Elsea C, Corbin AS, Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006;66:11156-65
   PubMed Web of Science ®Google Scholar
• Tiedt R, Hao-Shen H, Sobas MA, Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931-40
   PubMed Web of Science ®Google Scholar
• Xing S, Wanting TH, Zhao W, Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008;111:5109-17
   PubMed Web of Science ®Google Scholar
• Mullally A, Lane SW, Ball B, Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010;17:584-96
   PubMed Web of Science ®Google Scholar
• Akada H, Yan D, Zou H, Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010;115:3589-97
   PubMed Web of Science ®Google Scholar
• Dawson MA, Bannister AJ, Gottgens B, JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819-22
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663-71
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-70
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76
   PubMed Web of Science ®Google Scholar
• Marshall JL, Kindler H, Deeken J, Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005;23:31-7
   PubMed Web of Science ®Google Scholar
• Santos FP, Kantarjian HM, Jain N, Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2009;115:1131-6
   PubMed Web of Science ®Google Scholar
• Moliterno A, Hexner E, Roboz GJ, An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: update of 39 enrolled patients. Blood 2009;114: abstract 753
   PubMed Web of Science ®Google Scholar
• Hexner E, Goldberg JD, Prchal JT, A multicenter, open label Phase I/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the myeloproliferative disorders research consortium. Blood 2009;114: abstract 754
   Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
   PubMed Web of Science ®Google Scholar
• Nussenzveig RH, Cortes J, Sever M, Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 2009;90:58-63
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera and essential thrombocythemia refractory to hydroxyurea. Blood 2009;114: abstract 311
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, Response criteria for essential thrombocythemia and polycythemia vera: results of a European LeukemiaNet consensus conference. Blood 2009;113:4829-33
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R, Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20
   PubMed Web of Science ®Google Scholar
• Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:23-30
   PubMed Web of Science ®Google Scholar
• Pardanani A, Hood J, Lasho T, TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21:1658-68
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, Safety and efficacy of TG101348, a selective JAK2 inhibitor, in Myelofibrosis. J Clin Oncol 2011;29:789-96
   PubMed Web of Science ®Google Scholar
• Paquette R, Sokal L, Shah NP, A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 2008;112: abstract 2810
   PubMedGoogle Scholar
• Shah N, Olszynski P, Sokal L, A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 2008;112: abstract 98
   Web of Science ®Google Scholar
• Hedvat M, Huszar D, Herrmann A, The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho T, Smith G, CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5
   PubMed Web of Science ®Google Scholar
• Tyner JW, Bumm TG, Deininger J, CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40
   PubMed Web of Science ®Google Scholar
• Pardanani A, George, G, A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: significant response rates in Anemia, Splenomegaly, and Constitutional Symptoms. Blood 2010;117: abstract 460
   Google Scholar
• Verstovsek S, Odenike O, Scott B, Phase I dose-escalation trial of SB1518, a Novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/ polycythemia vera myelofibrosis. Blood 2009;114: abstract 3905
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55
   PubMed Web of Science ®Google Scholar
• Wang Y, Fiskus W, Chong DG, Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009;114:5024-33
   PubMed Web of Science ®Google Scholar
• Schwaller J, Frantsve J, Aster J, Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998;17:5321-33
   PubMed Web of Science ®Google Scholar
• Ho JM, Beattie BK, Squire JA, Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 1999;93:4354-64
   PubMed Web of Science ®Google Scholar
• Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Harvey RC, JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009;106:9414-18
   PubMed Web of Science ®Google Scholar
• Xiang Z, Zhao Y, Mitaksov V, Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111:4809-12
   PubMed Web of Science ®Google Scholar
• Walters DK, Mercher T, Gu TL, Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim YG, Soung YH, The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-6
   PubMed Web of Science ®Google Scholar
• Jelinek J, Oki Y, Gharibyan V, JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3
   PubMed Web of Science ®Google Scholar
• Pesu M, Candotti F, Husa M, Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-42
   PubMed Web of Science ®Google Scholar
• Quaedackers ME, Mol W, Korevaar SS, Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009;88:1002-9
   PubMed Web of Science ®Google Scholar
• Busque S, Leventhal J, Brennan DC, Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009;9:1936-45
   PubMed Web of Science ®Google Scholar
• van Gurp EA, Schoordijk-Verschoor W, Klepper M, The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009;87:79-86
   PubMed Web of Science ®Google Scholar
• van Gurp E, Weimar W, Gaston R, Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008;8:1711-18
   PubMed Web of Science ®Google Scholar
• Borie DC, Larson MJ, Flores MG, Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 2005;80:1756-64
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298-307
   PubMed Web of Science ®Google Scholar
• Williams W, Scherle P, Shi J, A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1 & 2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum 2008;58: abstract 714
   Google Scholar
• Punwani N, Gottlieb A, Birnbaum J, Efficacy and safety of topical INCB018424, a selective Janus kinase 1 and 2 (JAK1 and 2) inhibitor in psoriasis. J Am Acad Dermatol 2009;60: abstract 176
   Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa R, Safety and efficacy of a JAK1 & JAK2 inhibitor, INCB018424, in myelofibrosis. N Engl J Med 2010;363:1117-27
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib J, Jamieson C, A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood 2009;114: abstract 755
   Web of Science ®Google Scholar
• Jiang JK, Ghoreschi K, Deflorian F, Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008;51:8012-18
   PubMed Web of Science ®Google Scholar
• Liu PC, Caulder E, Li J, Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin Cancer Res 2009;15:6891-900
   PubMed Web of Science ®Google Scholar
• Baffert F, Regnier CH, De Pover A, Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther 2010;9:1945-55
   PubMed Web of Science ®Google Scholar
• Shide K, Kameda T, Markovtsov V, Efficacy of R723, a potent and selective JAK2 inhibitor, in JAK2 V617F-induced murine MPD model. Blood 2009;11: abstract 3897
   Google Scholar